Thank you, George’s Family!

We would like to say a massive thank you to the Family and Friends of the little fighter George who have raised £2,750 in support of TreatSMA.

At barely 12 weeks, George was diagnosed with the most severe form of spinal muscular atrophy – SMA type 1. Doctors confirmed that the boy will likely not survive past two years. George’s father contacted TreatSMA and thanks to the fantastic medical team at the Great Ormond Street Hospital, little George started receiving life-saving treatment Spinraza already two weeks later.

Now, after four injections, the brave boy is doing amazingly well. We at TreatSMA keep our fingers crossed for his full recovery and normal development.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more